Bristol Myers Squibb’s Opdivo-Based Perioperative Regimen Receives Positive CHMP Opinion for Resectable NSCLC Bristol Myers Squibb (NYSE: BMY) has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive…
Health Canada Approves 4Moving Biotech’s Phase 2a Trial for Knee Osteoarthritis 4Moving Biotech (4MB), a pioneering biotechnology company and a spin-off of 4P-Pharma, has received authorization from Health Canada to initiate its Phase 2a INFLAM MOTION clinical trial. This study…
Curatis Achieves 30% Sales Growth & Expands C-PTBE-01 Patient Reach Curatis Holding AG (SIX:CURN, ‘Curatis’) has reported strong business performance in 2024, achieving business revenues of CHF 6.9 million, with Curatis AG contributing to these figures for only eight months.…
Celltrion’s Remdantry™ Set for Canada Launch on April 1, 2025 Celltrion, Inc., a global biopharmaceutical leader, has announced that its biosimilar Remdantry™ will be available in Canada starting April 1, 2025. Previously marketed under the name Inflectra®, Remdantry™ represents the…
Invivoscribe Registers LeukoStrat® CDx FLT3 Assay in UK & Switzerland Invivoscribe, a global leader in precision diagnostics, has announced the successful registration of its LeukoStrat CDx FLT3 Mutation Assay in both the United Kingdom (UK) and Switzerland. This critical milestone…
Dial A Vet Expands to Canada, USA, and UK, Making Veterinary Care More Affordable Dial A Vet Expands Globally: Bringing Affordable Veterinary Care to Canada, USA, and UK Dial A Vet, Australia’s premier telehealth veterinary service, has announced its global…
Sweden Takes Key Step Toward a Smoke-Free World with New Policy Sweden has officially enshrined tobacco harm reduction in its public health policy, becoming the first nation to demonstrate that this approach is the most effective pathway to a smoke-free…
Xcell Biosciences and Royal Perth Hospital Partner to Develop Next-Generation Automated TIL Manufacturing Workflow Xcell Biosciences Australia PTY LTD (Xcellbio), an affiliate of Xcell Biosciences, Inc., a leading platform company specializing in cell and gene therapy applications, has announced a…
FDA Approves Blujepa (Gepotidacin) for Uncomplicated UTIs in Patients 12+ GSK plc (LSE/NYSE: GSK) has announced that the US Food and Drug Administration (FDA) has approved Blujepa (gepotidacin) for the treatment of uncomplicated urinary tract infections (uUTIs) in female adults…
KaliVir to Present at 2025 AACR Annual Meeting KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company specializing in the development of advanced oncolytic immunotherapies, has announced its participation in the upcoming American Association for Cancer Research (AACR) Annual Meeting. The event,…
Bayer Unveils New Heart Failure & Kidney Disease Research at ACC.25 Bayer has announced the presentation of 13 new data analyses from its comprehensive KERENDIA® (finerenone) clinical trial program at the American College of Cardiology (ACC) 74th Annual Scientific Session…
SOLVE FSHD Partners with Transcripta Bio to Accelerate Drug Discovery for FSHD SOLVE FSHD, a venture philanthropy organization committed to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), has announced a strategic collaboration with Transcripta Bio, an innovative AI-driven drug discovery…